-
CD52 Expression(Post)
What is CD52? Cluster Of Differentiation 52 (CD52) is a highly expressed membrane glycoprotein which is present on the surface of immune cell
Cancer Metabolism: Tumorigenesis, Metabolic Therapy & The Warburg Effect(Post)Cancer Metabolism is the mechanism by which cancer cells make energy in order for them to grow and spread. Even in the presence of oxygen, cancer cells increase glucose uptake and produce lactate,
SIRPα Inhibition: Clearing Tumors by Promoting Phagocytosis(Post)Cancer cells are adept at avoiding destruction by the immune system, often exploiting specific pathways to escape detection and elimination. One of these key mechanisms involves the SIRPα
マルチプレックス ELISA(Page)マルチプレックス ELISA(GeniePlex)| Assay Genie | Assay Genie
Embryonic Induced Pluripotent Stem Cell Differentiation: Pathways and Lineage-Specific Markers(Post)Embryonic induced pluripotent stem cells (iPSCs) hold immense potential in the field of regenerative medicine due to their ability to differentiate into various cell types. Understanding the diffe
Leukocytes : Basics to Diseases(Post)Only 1% of our blood is made up of white blood cells, but they have a significant impact. Alternatively referred to as leukocytes, white blood cells. We are shielded from disease and
Alsevalimab: Targeting CD47 for Cancer Research and Treatment(Post)Quick Facts About AlsevalimabWhat is Alsevalimab?Alsevalimab is a monoclonal antibody targeting CD47, a protein involved in immune evasion by cancer cells. By blocking CD47, Alsevalimab
CTLA-4 in Breast Cancer: Insights for Immunotherapy(Post)The Role of CTLA-4 in Breast Cancer: Implications for ImmunotherapyBreast cancer (BC) remains one of the most prevalent malignancies affecting women worldwide, with significant morbidity and mortality
Daratumumab: Advancing Research in Multiple Myeloma and Beyond(Post)Key Facts About DaratumumabWhat is Daratumumab?Daratumumab is a monoclonal antibody that targets CD38, a protein highly expressed on the surface of multiple myeloma cells.How does Daratu
Apoptosis Pathway(Page) 세포 용해를위한 소니케이션(초음파 처리 분해) 프로토콜 (Page) Cellular Senescence in Cancer Immunotherapy: The Double-Edged Sword(Post)Cellular Senescence in Cancer Immunotherapy: The Double-Edged Sword In the intricate world of cancer biology, some of our body's most potent defense mechanisms can paradoxically turn against us. Cell
Red Blood Cell Peroxidase Interference in Competitive ELISA(Post)QUICK ANSWER A researcher ran a competitive 2,3-bisphosphoglycerate (2,3-BPG) ELISA on red blood cell (RBC) lysate. The standard curve was textbook, yet every lysate sample read at the
Neutrophils - Cells of the Immune System(Post)The immune system is the body’s main defence against infection. In order to function properly, the immune system must be able to detect and protect against infinite agents such as
Microglia and Neuroinflammation(Page) Tiragolumab: Unlocking New Horizons in Cancer Immunotherapy(Post)Quick Facts About TiragolumabWhat is Tiragolumab?Tiragolumab is an anti-TIGIT monoclonal antibody developed to enhance immune responses against cancer cells. It is currently under invest
Blood Coagulation Pathway: Factors, Cascade & Disorders [Guide](Post)Haematology · CoagulationBlood Coagulation Pathway: Factors, Cascade and DisordersThe coagulation cascade is usually taught as two pathways converging on a common one. That framework maps neatly onto
Une courbe par plaque pour la courbe standard ELISA au laboratoire(Post)Une courbe par plaque pour la courbe standard ELISA au laboratoire Une courbe standard ELISA convertit les densités optiques mesurées en concentrations exploitables, à partir d’une série d’étalons de
Icatolimab: Revolutionizing the Fight Against Cancer via CD47 Targeting(Post)Quick Facts About IcatolimabWhat is Icatolimab?Icatolimab is a monoclonal antibody designed to target CD47, a protein that cancer cells use to evade immune detection.How does Icatolimab
Litifilimab: A Promising Anti-BDCA2 Antibody for Lupus Treatment(Post)Quick Facts About LitifilimabWhat is Litifilimab?Litifilimab is a monoclonal antibody developed by Biogen targeting BDCA2, a receptor on plasmacytoid dendritic cells (pDCs), to regulate